Phosphate binder equivalent dose (PBED) relative to Velphoro (%)*1
*Based on an analysis of comparative clinical studies that roughly established an equivalent dose for phosphate binders relative to the phosphate binding capacity of calcium carbonate.1
See the mechanism behind Velphoro potency
Phosphate is ingested and distributed throughout the body. Velphoro is highly selective for phosphorus in the pH range of the digestive tract (1.2 to 7.5).2 Phosphate from food binds to form phosphate-Velphoro complex, which is then excreted through the large intestine.3
DOPPS=Dialysis Outcomes and Practice Patterns Study
KDIGO=Kidney Disease: Improving Global Outcomes
References: 1. Coyne DW, Larson DS, Delmez JA. Bone disease. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 5th ed. Wolters Kluwer Health; 2015:665-692. 2. Wilhelm M, Gaillard S, Viatcheslav R, Funk F. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol. 2014;(81)4:251-258. 3. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America; 2020. 4. Dialysis Outcomes and Practice Patterns Study Program. DOPPS Practice Monitor. Serum phosphorus (most recent) categories. https://www.dopps.org/DPM/Files/phosphmgdl_c_overallTAB.htm. Accessed May 25, 2021. 5. Kidney Disease: Improving Global Outcomes. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2017;7(suppl 1):1-59. 6. Kidney Disease: Improving Global Outcomes. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009;76(suppl 113):1-140. 7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-S201. 8. Dialysis Outcomes and Practice Patterns Study Program. DOPPS Practice Monitor. Phosphate binder use, by type. https://www.dopps.org/DPM/Files/pbgroup_c_overallTAB.htm. Accessed May 25, 2021. 9. Data on file. Fresenius Medical Care North America, Waltham, MA.